Absorbed dose profiles for (32)P, (90)Y, (188)Re, (177)Lu, (153)Sm and (169)Er: radionuclides used in radiosynoviortheses treatment.
The main objective of this paper was to obtain the absorbed dose profiles for radionuclides of frequent or potential use in radiosynoviortheses. These profiles reveal the absorbed dose per activity of injected radionuclide (Gy/h*MBq) in the synovial membrane and the articular cartilage. The researched radionuclides were (32)P, (90)Y, (188)Re, (177)Lu, (153)Sm and (169)Er. The therapeutic range of each radionuclides in synovial tissue were also calculated. This range determines the synovial thickness that can be sufficiently irradiated and thus successfully treated. The S values for the synovial membrane and articular cartilage were calculated using as a model a cylinder with the source uniformly distributed in its volume. The synovial membrane was simulated varying the radius of the cylinder (from 0.5cm to 9cm) and its height (from 0.01cm to 0.04cm). The area in the base of the cylinder represents different sizes of the synovial surface (small, medium and large joints). The height of the cylinder represents different stages of the progression of the rheumatoid arthritis. The same model was used to simulate the articular cartilage but, the source was uniformly distributed into a cylindrical slab (0.01cm height and 1cm of radius. The results obtained allow the estimation of the dose that will be delivered to the synovial membrane and the articular cartilage for different joint sizes and different stages of progression of the rheumatoid arthritis (RA).
Torres
M
M
Radiation Protection Department, Isotopes Centre, Carretera la Rada, Havana, Cuba. mtorres@centis.edu.cu
Ayra
E
E
Albuerne
O
O
Montano Delgado
M A
MA
D000042:Absorption; D000465:Algorithms; D001172:Arthritis, Rheumatoid / Q000378:metabolism / Q000532:radiotherapy*; D001610:Beta Particles / Q000627:therapeutic use; D002358:Cartilage, Articular / Q000378:metabolism / Q000528:radiation effects; D004871:Erbium / Q000493:pharmacokinetics / Q000627:therapeutic use; D005720:Gamma Rays / Q000627:therapeutic use; D006801:Humans; D008187:Lutetium / Q000493:pharmacokinetics / Q000627:therapeutic use; D008348:Manikins; D009010:Monte Carlo Method; D010761:Phosphorus Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use; D011868:Radioisotopes / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011874:Radiometry / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D012211:Rhenium / Q000493:pharmacokinetics / Q000627:therapeutic use; D012493:Samarium / Q000493:pharmacokinetics / Q000627:therapeutic use; D013583:Synovial Membrane / Q000378:metabolism / Q000528:radiation effects; D015021:Yttrium Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use
D010761:Phosphorus Radioisotopes; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D012493:Samarium; D008187:Lutetium; D012211:Rhenium; D004871:Erbium